Kasi, A., Iglesias, J. L. (2025). Interim open-label phase 1 results of misetionamide (GP-2250): A small molecule antineoplastic targeting three major transcription factors.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.4177